Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 16;12(32):6538-6542.
doi: 10.12998/wjcc.v12.i32.6538.

Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression

Basma M E Mohamed  1 , Mohamed E A Abdelrahim  2
Affiliations
Editorial

Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression

Basma M E Mohamed et al. World J Clin Cases. .

Abstract

In this editorial, we comment on the article by Lei et al, with a specific focus on the timing of the initiation of the antifibrotic agent pirfenidone (PFD) in the management of idiopathic pulmonary fibrosis (IPF) and its impact on lung function of IPF patients. PFD is an antifibrotic agent that is widely used in the management of IPF in both early and advanced stages. It inhibits various pathways and has antifibrotic, anti-inflammatory, and antioxidant properties. Despite dosage lowering, PFD slowed IPF progression and maintained functional capacity. The 6-min walk distance test indicated that patients tolerated adverse events well, and PFD significantly reduced the incidence of progression episodes and death. Even when a single disease-progression event occurred, continuing PFD treatment had benefits.

Keywords: Idiopathic pulmonary fibrosis; Pirfenidone; Pirfenidone anti-inflammatory mechanism; Pirfenidone antifibrotic activity; Timing impact.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors have no conflicts of interest to disclose.

References

    1. Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Ann Am Thorac Soc. 2019;16:927–930. - PMC - PubMed
    1. Hilberg O, Simonsen U, du Bois R, Bendstrup E. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J. 2012;6:131–143. - PubMed
    1. Kang J, Choi J, Song WY, Choi J, Lee S, Park C. In vivo pharmacokinetic and pharmacodynamic study of inhalable pirfenidone microparticles prepared via high-energy bead milling. J Pharm Investig. 2023;53:869–879.
    1. Antar SA, Saleh MA, Al-Karmalawy AA. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2. Life Sci. 2022;309:121048. - PMC - PubMed
    1. Aimo A, Spitaleri G, Nieri D, Tavanti LM, Meschi C, Panichella G, Lupón J, Pistelli F, Carrozzi L, Bayes-Genis A, Emdin M. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev. 2022;8:e12. - PMC - PubMed

Publication types

LinkOut - more resources